High throughput screening News and Research

RSS

High-throughput screening (HTS) allows scientists to test thousands of samples at once. These samples can be of a wide variety, and include, but are not limited to, amino acids, chemical compounds or cells.

Small molecule drug can attenuate the triggers of neuroinflammation, preclinical study shows

Neuroinflammation can worsen outcomes in stroke, traumatic brain injury, or spinal cord injury, as well as accelerate neurodegenerative diseases like ALS, Parkinson's, or Alzheimer's. This suggests that limiting neuroinflammation may represent a promising new approach to treat neurological diseases and neuropathic pain that are driven by neuroinflammation.

24 Sep 2021

UTSA receives $3.2 million CPRIT grant for developing new approach to fight against cancer

The University of Texas at San Antonio has been awarded a five-year $3.2 million grant from the Cancer Prevention & Research Institute of Texas.

2 Sep 2021

First-in-kind kidney cancer drug developed at UTSW receives FDA approval

A first-in-kind kidney cancer drug developed from laboratory and translational studies conducted at UT Southwestern Medical Center received approval from the Food and Drug Administration, providing a new treatment for patients with familial kidney cancer.

24 Aug 2021

Scientists identify calpeptin as potential inhibitor of SARS-CoV-2

A team of US-based scientists has recently conducted a robust high-throughput screening to identify potential entry inhibitors of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The screening identifies calpeptin as a potent and highly specific inhibitor of SARS-CoV-2 and its variants. The study is currently available on the bioRxiv* preprint server.

9 Aug 2021

A path to treat currently untreatable cases of cystic fibrosis is clearly achievable, study suggests

An experimental drug reported in Nature Communications suggests that a "path is clearly achievable" to treat currently untreatable cases of cystic fibrosis disease caused by nonsense mutations.

19 Jul 2021

New screening method tests the effectiveness of drug compounds that 'glue' proteins together

A new screening method that can test the effectiveness of therapeutic molecules designed to 'glue' proteins together in the body has been developed by researchers at the University of Birmingham and the University of Leicester.

7 Jul 2021

New article focuses on drug discovery targeting SARS-CoV-2

The July edition of SLAS Discovery is a Special Edition featuring the cover article, "Development of a High-Throughput Screening Assay to Identify Inhibitors of the SARS-CoV-2 Guanine-N7-Methyltransferase Using RapidFire Mass Spectrometry" by Lesley-Anne Pearson, Charlotte J. Green, Ph.D., De Lin, Ph.D., Alain-Pierre Petit, Ph.D., David W. Gray, Ph.D., Victoria H. Cowling, Ph.D., and Euan A. F. Fordyce, Ph.D., (Drug Discovery Unit, School of Life Sciences, University of Dundee, Dundee, UK).

1 Jul 2021

Optibrium Publishes Major Peer-Reviewed Study on AI Applications to Global Pharma Data

Optibrium Limited today announced the publication of a peer-reviewed study in Applied AI Letters, “Deep Imputation on Large-Scale Drug Discovery Data”.

From Optibrium Ltd. 29 Jun 2021

Study reviews natural drug candidates for potential treatment of COVID-19

A recent paper in the Saudi Journal of Biological Sciences seeks to open up new approaches by reviewing a list of compounds derived from plants and other natural sources, which have potential inhibitory activity against the coronavirus.

21 Jun 2021

Waters launches new RUO LC-MS test method to advance infectious disease research

Waters Corporation today introduced a new RUO LC-MS test method to advance critical infectious disease research.

4 Jun 2021

Scientists identify many existing drugs with antiviral activity against coronavirus

Mining the world's most comprehensive drug repurposing collection for COVID-19 therapies, scientists have identified 90 existing drugs or drug candidates with antiviral activity against the coronavirus that's driving the ongoing global pandemic.

3 Jun 2021

New drug effectively prevents severe COVID-19 in mice infected with SARS-CoV-2

The drug diABZI which activates the body's innate immune response -- was highly effective in preventing severe COVID-19 in mice that were infected with SARS-CoV-2, according to scientists in the Perelman School of Medicine at the University of Pennsylvania

29 May 2021

Waters Introduces the SARS-CoV-2 LC-MS Kit (RUO) to Advance Clinical Research of Infectious Diseases

Waters Corporation today introduced a new RUO LC-MS test method to advance critical infectious disease research.

From Waters Corporation 27 May 2021

Repurposed gout medication (probenecid) shows potent inhibition of SARS-CoV-2 replication

New research by a team of scientists in the USA describes the potential utility of a drug called probenecid, commonly used to treat gout, to treat this devastating viral illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the causative virus of COVID-19.

25 May 2021

ErbB inhibitor lapatinib exhibits potent anti-SARS-CoV-2 activity

A team of scientists from the USA and Belgium has recently revealed that the ErbB family of receptor tyrosine kinases play a vital role in regulating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lifecycle in host cells and that inhibition of these receptors can protect against SARS-CoV-2-induced acute and chronic lung injuries and inflammation.

18 May 2021

Four-part small-molecule cocktail can prevent cellular stress

Researchers at the National Institutes of Health (NIH) have devised a four-part small-molecule cocktail that can protect stem cells called induced pluripotent stem cells (iPSCs) from stress and maintain normal stem cell structure and function.

4 May 2021

Monoclonal antibody neutralizes all SARS-CoV-2 variants of concern

Researchers in Canada and the United States have identified a monoclonal antibody that potently neutralizes variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent responsible for the ongoing coronavirus disease 2019 (COVIdD-19) pandemic.

3 May 2021

Competitive multiplex binding assay can monitor SARS-CoV-2 immune responses using nanobodies

Researchers at the Eberhard Karls University and the University of Tübingen in Germany described 11 unique nanobodies (Nbs) specific for the SARS-CoV-2 spike receptor-binding domain (RBD), of which 8 Nbs potentially inhibit the connection of RBD with the angiotensin-converting enzyme 2 (ACE2).

3 May 2021

New genetically encoded sensor helps detect drugs of abuse

A genetically encoded sensor to detect hallucinogenic compounds has been developed by researchers at the University of California, Davis. Named psychLight, the sensor could be used in discovering new treatments for mental illness, in neuroscience research and to detect drugs of abuse. The work is published April 28 in the journal Cell.

29 Apr 2021

Probiotic L. acidophilus can effectively treat intestinal inflammation, research shows

Intestinal epithelial tight junctions (TJs) act as a functional and structural barrier against harmful antigens that promote intestinal inflammation in inflammatory bowel disease (IBD) and other inflammatory conditions of the gut.

20 Apr 2021